Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome